These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 29408056)
1. The epigenetic factor KDM2B regulates cell adhesion, small rho GTPases, actin cytoskeleton and migration in prostate cancer cells. Zacharopoulou N; Tsapara A; Kallergi G; Schmid E; Tsichlis PN; Kampranis SC; Stournaras C Biochim Biophys Acta Mol Cell Res; 2018 Apr; 1865(4):587-597. PubMed ID: 29408056 [TBL] [Abstract][Full Text] [Related]
2. The Epigenetic Factor KDM2B Regulates EMT and Small GTPases in Colon Tumor Cells. Zacharopoulou N; Tsapara A; Kallergi G; Schmid E; Alkahtani S; Alarifi S; Tsichlis PN; Kampranis SC; Stournaras C Cell Physiol Biochem; 2018; 47(1):368-377. PubMed ID: 29772566 [TBL] [Abstract][Full Text] [Related]
3. The histone demethylase KDM2B activates FAK and PI3K that control tumor cell motility. Zacharopoulou N; Kallergi G; Alkahtani S; Tsapara A; Alarifi S; Schmid E; Sukkar B; Kampranis S; Lang F; Stournaras C Cancer Biol Ther; 2020 Jun; 21(6):533-540. PubMed ID: 32175798 [TBL] [Abstract][Full Text] [Related]
4. KDM2B is involved in the epigenetic regulation of TGF-β-induced epithelial-mesenchymal transition in lung and pancreatic cancer cell lines. Wanna-Udom S; Terashima M; Suphakhong K; Ishimura A; Takino T; Suzuki T J Biol Chem; 2021; 296():100213. PubMed ID: 33779563 [TBL] [Abstract][Full Text] [Related]
5. KDM2B mediates the Wnt/β-catenin pathway through transcriptional activation of PKMYT1 via microRNA-let-7b-5p/EZH2 to affect the development of non-small cell lung cancer. Zhang X; Yin Z; Li C; Nie L; Chen K Exp Cell Res; 2022 Aug; 417(2):113208. PubMed ID: 35580699 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of microRNA let-7b expression by KDM2B promotes cancer progression by targeting EZH2 in ovarian cancer. Kuang Y; Xu H; Lu F; Meng J; Yi Y; Yang H; Hou H; Wei H; Su S Cancer Sci; 2021 Jan; 112(1):231-242. PubMed ID: 33091189 [TBL] [Abstract][Full Text] [Related]
7. Transcriptional regulation of amino acid metabolism by KDM2B, in the context of ncPRC1.1 and in concert with MYC and ATF4. Chavdoula E; Anastas V; La Ferlita A; Aldana J; Carota G; Spampinato M; Soysal B; Cosentini I; Parashar S; Sircar A; Nigita G; Sehgal L; Freitas MA; Tsichlis PN Metabolism; 2024 Jan; 150():155719. PubMed ID: 37935302 [TBL] [Abstract][Full Text] [Related]
8. Lysine-specific demethylase 2B (KDM2B)-let-7-enhancer of zester homolog 2 (EZH2) pathway regulates cell cycle progression and senescence in primary cells. Tzatsos A; Paskaleva P; Lymperi S; Contino G; Stoykova S; Chen Z; Wong KK; Bardeesy N J Biol Chem; 2011 Sep; 286(38):33061-9. PubMed ID: 21757686 [TBL] [Abstract][Full Text] [Related]
9. KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL. Kurt IC; Sur I; Kaya E; Cingoz A; Kazancioglu S; Kahya Z; Toparlak OD; Senbabaoglu F; Kaya Z; Ozyerli E; Karahüseyinoglu S; Lack NA; Gümüs ZH; Onder TT; Bagci-Onder T Cell Death Dis; 2017 Jun; 8(6):e2897. PubMed ID: 28661478 [TBL] [Abstract][Full Text] [Related]
10. Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing p15INK4B, p16INK4A, and p57KIP2 transcription. Zheng Q; Fan H; Meng Z; Yuan L; Liu C; Peng Y; Zhao W; Wang L; Li J; Feng J Acta Biochim Biophys Sin (Shanghai); 2018 Sep; 50(9):897-904. PubMed ID: 30060056 [TBL] [Abstract][Full Text] [Related]
11. Interplay between the Epigenetic Enzyme Lysine (K)-Specific Demethylase 2B and Epstein-Barr Virus Infection. Vargas-Ayala RC; Jay A; Manara F; Maroui MA; Hernandez-Vargas H; Diederichs A; Robitaille A; Sirand C; Ceraolo MG; Romero-Medina MC; Cros MP; Cuenin C; Durand G; Le Calvez-Kelm F; Mundo L; Leoncini L; Manet E; Herceg Z; Gruffat H; Accardi R J Virol; 2019 Jul; 93(13):. PubMed ID: 30996097 [TBL] [Abstract][Full Text] [Related]
12. The KDM2B- let-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy. Karoopongse E; Yeung C; Byon J; Ramakrishnan A; Holman ZJ; Jiang PY; Yu Q; Deeg HJ; Marcondes AM PLoS One; 2014; 9(9):e107817. PubMed ID: 25225797 [TBL] [Abstract][Full Text] [Related]
14. KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs. Tzatsos A; Paskaleva P; Ferrari F; Deshpande V; Stoykova S; Contino G; Wong KK; Lan F; Trojer P; Park PJ; Bardeesy N J Clin Invest; 2013 Feb; 123(2):727-39. PubMed ID: 23321669 [TBL] [Abstract][Full Text] [Related]
15. NDY1/KDM2B functions as a master regulator of polycomb complexes and controls self-renewal of breast cancer stem cells. Kottakis F; Foltopoulou P; Sanidas I; Keller P; Wronski A; Dake BT; Ezell SA; Shen Z; Naber SP; Hinds PW; McNiel E; Kuperwasser C; Tsichlis PN Cancer Res; 2014 Jul; 74(14):3935-46. PubMed ID: 24853546 [TBL] [Abstract][Full Text] [Related]
16. Combined expression levels of KDM2A and KDM2B correlate with nucleolar size and prognosis in primary breast carcinomas. De Nicola I; Guerrieri AN; Penzo M; Ceccarelli C; De Leo A; Trerè D; Montanaro L Histol Histopathol; 2020 Oct; 35(10):1181-1187. PubMed ID: 32901907 [TBL] [Abstract][Full Text] [Related]
17. KDM2B/FBXL10 targets c-Fos for ubiquitylation and degradation in response to mitogenic stimulation. Han XR; Zha Z; Yuan HX; Feng X; Xia YK; Lei QY; Guan KL; Xiong Y Oncogene; 2016 Aug; 35(32):4179-90. PubMed ID: 26725323 [TBL] [Abstract][Full Text] [Related]